S100B Levels in Patients with Type 2 Diabetes Mellitus and Co-Occurring Depressive Symptoms

Table 3

Linear regression of patients’ characteristics with LnS100B.

	beta	95% confidence interval	P
Age	-0.057	-0.320 -0.210	0.960
Female	-0.095	-0.943-0.458	0.502
BMI	-0.098	-0.063-0.057	0.923
Current smoking	-2.08	-1.314-0.188	0.139
CAD	0.044	-1.712-0.973	0.757
Arterial Hypertension	0.037	-0.617-0.800	0.796
MAP	-0.187	-0.051-0.010	0.185
Duration of diabetes	0.105	-0.002-0.004	0.459
MDRD	-0.202	-0.030-0.005	0.150
HbA1c	0.072	-0.211-0.357	0.610
TNF-a	-0.135	-0.700-0.199	0.341
Insulin	0.026	-0.767-0.920	0.856
Metformin	0.092	-0.484-0.951	0.516
DPP4 inhibitors	-0.072	-0.987-0.587	0.613
Sulphonylureas	-0.056	-0.896-0.601	0.694
ACE/ARBs	-0.027	-0.729-0.602	0.849
b-blockers	0.098	0.470-0.964	0.492
Antiplatelet treatment	0.113	-0.423-0.985	0.426
Statin treatment	0.169	-0.261-1.054	0.232
Depressive symptoms	0.084	-0.470-0.871	0.552
Hamilton score	0.019	-0.098-1.112	0.894
Zung self-assessment score	0.048	-0.024-0.033	0.738

BMI: body mass index, TIA: transient ischemic attack, CAD: cardiovascular disease, MAP: Mean Arterial Pressure (MAP = [(2 x diastolic)+systolic]/3, MDRD: GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) (mL/min/1.73 m2), HbA1c: glycated hemoglobin, TNFa: tumor necrosis factor a, S100B: S100 calcium binding peptide b, DPP4 inhibitors: dipeptidyl-peptidase 4 inhibitors, ACE: angiotensin-converting-enzyme inhibitor, and ARBs: angiotensin receptor blockers.